3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) recently made the final payment to CancerCare Manitoba (CCMB) for the purchase of intellectual property. All patents were assigned from CCMB to 3DS in June 2014.
Quarterly cash payments made by 3DS to CCMB totaled $269,617.75 over a 24- month period. CCMB retains a 1.5% royalty on all gross revenues derived from the commercialization of the patent rights and related products.
"CCBM has been an excellent partner and we see a number of opportunities for further collaboration based on some very recent and productive discussions," Jason Flowerday, CEO of 3DS, said in a statement.
The intellectual property acquired from CCMB is at the core of 3DS’ proprietary TeloView software platform, which has successfully identified and correlated distinct 3D telomere signatures in 13 different cancers and Alzheimer's disease.
“We believe that TeloView is a valuable and disruptive technology that will lead to multiple commercial tests as well as collaborations with biopharma partners that share our commitment to personalized medicine," he added.